ILMN - will it finally break the resistant?

Illumina , Inc. ILMN has been gaining from robust segmental growth and increased demand for its products. The company’s focus on partnerships and worldwide expansion to drive growth are expected to contribute further. However, stiff competition and a tough funding environment remain concerns.

Over the past three months, the Zacks Rank #3 (Hold) stock has outperformed its industry. The stock has gained 30.4% compared with the industry’s growth of 18.6%. Meanwhile, the S&P 500 rallied 14.4% in the same time frame.

The renowned life sciences company, which has a market capitalization of $52.93 billion, provides tools and integrated systems for analysis of genetic variation and function. The company projects 11% growth for the next five years and expects to maintain strong segmental performance. Further, it has a trailing four-quarter positive earnings surprise of 19.3%, on average.


Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out